---
schema_version: "secwatch.filing_event.v1"
accession: "0001683168-24-007758"
form_type: "8-K"
ticker: "SBFM"
cik: "0001402328"
company_name: "Sunshine Biopharma Inc."
filed_at: "2024-11-07T23:59:59+00:00"
generated_at: "2026-05-30T03:24:40.086862+00:00"
event_type: "earnings"
sentiment: "neutral"
materiality_score: 0.6
calibrated_materiality_score: 0.6
confidence: "high"
source: SEC EDGAR
---

# Sunshine Biopharma Q3 2024 revenues up 42% YoY; net loss widens 84% in quarter

## Summary
- Q3 2024 gross revenues $8.44M, up 42% from $5.96M in Q3 2023; YTD revenues $25.28M, up 54%.
- Q3 net loss $(1.20M) compared to $(0.65M) in Q3 2023, a YoY increase of 84%.
- YTD net loss $(2.98M) vs $(3.26M) in prior year period, an improvement of 9%.
- Shareholders' equity grew 18% to $25.04M from $21.21M at Dec 31, 2023.
- Growth driven by new product launches and expanded marketing via Canadian subsidiary Nora Pharma.

## SEC filing metadata
- accession: 0001683168-24-007758
- form_type: 8-K
- ticker: SBFM
- cik: 0001402328
- company_name: Sunshine Biopharma Inc.
- filed_at: 2024-11-07T23:59:59+00:00
- event_type: earnings
- sentiment: neutral
- materiality_score: 0.6
- calibrated_materiality_score: 0.6
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1402328/000168316824007758/0001683168-24-007758-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1402328/000168316824007758/sunshine_8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001683168-24-007758
- JSON: https://secwatch.observer/filing/0001683168-24-007758.json
- Plain text: https://secwatch.observer/filing/0001683168-24-007758.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.